OOIR: Observatory of International Research

Papers

(The H4-Index of Lancet Rheumatology is 43. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Composite endpoints for Sjögren's Syndrome	529
Is it Autumn for colchicine and osteoarthritis?	470
Cardiovascular risk in gout: time for action	274
Thank you to The Lancet Rheumatology's peer reviewers in 2023	229
FDA approval for anifrolumab in patients with lupus	184
Pausing drugs and spacing vaccines: an open question	173
The inclusion of Indigenous voices in health research	156
Rheumatic cognitive impairment: a new clinical entity?	142
CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case series	133
Immunoglobulin, glucocorticoid, or combined therapy for multisystem inflammatory syndrome in children	132
Brachial plexopathy: an unusual manifestation of Takayasu arteritis	127
Thrombotic microangiopathy as a presentation of anti-synthetase syndrome	126
Survival in patients with rheumatoid arthritis and recently diagnosed early-stage colorectal, lung, or prostate cancer receiving tumour necrosis factor inhibitors: a retrospective cohort study	109
Detection of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease using home monitoring in the Netherlands (DecreaSSc): a prospective, observational s	107
The projected burden of arthritis among adults and children in Australia to the year 2040: a population-level forecasting study	107
Tumour necrosis factor inhibitor safety in rheumatoid arthritis-associated interstitial lung disease	104
Performance of large language models in rheumatology board-like questions: accuracy, quality, and safety	103
Integrating evidence from lived experience of Aboriginal people and clinical practice guidelines to develop arthritis educational resources: a mixed-methods study	88
Cardiovascular events in patients with gout initiating urate-lowering therapy with or without colchicine for flare prophylaxis: a retrospective new-user cohort study using linked primary care, hospita	86
Research in Brief	82
Toxic epidermal necrosis-like acute cutaneous lupus erythematosus	78
Novel COVID-19 therapies: the road ahead for rheumatology	76
Do JAK inhibitors affect immune response to COVID-19 vaccination? Data from the MAJIK-SFR Registry	74
Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a single-centre cohort stud	72
Brett Thombs: an unconventional journey	70

Research in Brief	69
Monoclonal gammopathy of clinical significance: what the rheumatologist needs to know	68
Survivorship of revised and multiply revised knee replacements	59
Research in Brief	57
Research in Brief	55
Research in Brief	54
The role of skin ultrasound in systemic sclerosis: looking below the surface to understand disease evolution	54
Reigniting the burnt-out health-care workforce	53
Cervical spinal gout	49
Correction to Lancet Rheumatol 2020; 2: e557–64	49
Molecular signature-based decision making in the era of targeted therapies for systemic lupus erythematosus	49
Research in Brief	48
Long-awaited action on rare diseases	47
Pandemic to endemic: optimising COVID-19 immunity	46
Can contextual factors improve clarity of the results from clinical trials of low back pain?	45
Patient–researcher co-presentation of research results to people living with systemic sclerosis	44
The influence of safety warnings on the prescribing of JAK inhibitors	44
Steroids or intravenous immunoglobulin as first line in MIS-C in LMICs	44
Titilola (Lola) Falasinnu: looking out for the overlooked	43
Research in Brief	43
Towards improving the Global Burden of Disease estimates for low back pain	43